{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:33:37Z","timestamp":1776353617830,"version":"3.51.2"},"reference-count":44,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.5551\/jat.65334","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:13:17Z","timestamp":1734041597000},"page":"786-803","source":"Crossref","is-referenced-by-count":7,"title":["Triglycerides and the Risk of Atherosclerotic Cardiovascular Events Across Different Risk Categories"],"prefix":"10.5551","volume":"32","author":[{"given":"Hiroyuki","family":"Mizuta","sequence":"first","affiliation":[{"name":"Tokushukai Isen Clinic"},{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"},{"name":"Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So","family":"Ikebe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Yamanouchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Investigation, Kumamoto University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University"},{"name":"Department of Clinical Investigation, Kumamoto University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"},{"name":"Department of Clinical Investigation, Kumamoto University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J, 2006; 70: 1249-1255","DOI":"10.1253\/circj.70.1249"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A and Miyamoto Y. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. J Atheroscler Thromb, 2014; 21: 784-798","DOI":"10.5551\/jat.19356"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nakai M, Watanabe M, Kokubo Y, Nishimura K, Higashiyama A, Takegami M, Nakao YM, Okamura T and Miyamoto Y. Development of a Cardiovascular Disease Risk Prediction Model Using the Suita Study, a Population-Based Prospective Cohort Study in Japan. J Atheroscler Thromb, 2020; 27: 1160-1175","DOI":"10.5551\/jat.48843"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J and Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM, Jr., Ridker PM, Grundy SM and Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol, 2014; 64: 485-494","DOI":"10.1016\/j.jacc.2014.02.615"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S and Ogawa H. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol, 2015; 66: 495-507","DOI":"10.1016\/j.jacc.2015.05.065"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E and Califf RM. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS and Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y and Nicholls SJ. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med, 2023; 388: 1353-1364","DOI":"10.1056\/NEJMoa2215024"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD and Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT and Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation, 2007; 115: 450-458","DOI":"10.1161\/CIRCULATIONAHA.106.637793"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T and Pennathur S. Triglycerides and Cardiovascular Disease. Circulation, 2011; 123: 2292-2333","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G and Woodward M. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation, 2004; 110: 2678-2686","DOI":"10.1161\/01.CIR.0000145615.33955.83"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Bor\u00e9n J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E and Langlois M. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J, 2016; 37: 1944-1958","DOI":"10.1093\/eurheartj\/ehw152"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Higashiyama A, Wakabayashi I, Okamura T, Kokubo Y, Watanabe M, Takegami M, Honda-Kohmo K, Okayama A and Miyamoto Y. The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. J Atheroscler Thromb, 2021; 28: 1275-1288","DOI":"10.5551\/jat.62730"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES and Everett BM. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022; 387: 1923-1934","DOI":"10.1056\/NEJMoa2210645"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K and Shirato K. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC and Ballantyne CM. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22","DOI":"10.1056\/NEJMoa1812792"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L and Wiklund O. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, Sakamoto T, Tsujita K, Hagiwara N, Miyazaki S, Ako J, Arai H, Ishii H, Origuchi H, Shimizu W, Takemura H, Tahara Y, Morino Y, Iino K, Itoh T, Iwanaga Y, Uchida K, Endo H, Kongoji K, Sakamoto K, Shiomi H, Shimohama T, Suzuki A, Takahashi J, Takeuchi I, Tanaka A, Tamura T, Nakashima T, Noguchi T, Fukamachi D, Mizuno T, Yamaguchi J, Yodogawa K, Kosuge M, Kohsaka S, Yoshino H, Yasuda S, Shimokawa H, Hirayama A, Akasaka T, Haze K, Ogawa H, Tsutsui H and Yamazaki T. JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circ J, 2019; 83: 1085-1196","DOI":"10.1253\/circj.CJ-19-0133"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS and Yeboah J. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A and Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Carey RM, Lima JAC, Oparil S, Yasunaga H and Komuro I. Association of Blood Pressure Classification Using the 2017 American College of Cardiology\/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. Circulation, 2021; 143: 2244-2253","DOI":"10.1161\/CIRCULATIONAHA.120.052624"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kaneko H, Itoh H, Kiriyama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Takeda N, Morita H, Yasunaga H and Komuro I. Lipid Profile and Subsequent Cardiovascular Disease among Young Adults Aged \uff1c50 Years. Am J Cardiol, 2021; 142: 59-65","DOI":"10.1016\/j.amjcard.2020.11.038"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kawasaki R, Konta T and Nishida K. Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: A real-world observational analysis of a health claims database. Diabetes Obes Metab, 2018; 20: 2351-2360","DOI":"10.1111\/dom.13372"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Goto A, Goto M, Terauchi Y, Yamaguchi N and Noda M. Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. J Am Heart Assoc, 2016; 5: e002875","DOI":"10.1161\/JAHA.115.002875"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Raposeiras-Roubin S, Rossell\u00f3 X, Oliva B, Fern\u00e1ndez-Friera L, Mendiguren JM, Andr\u00e9s V, Bueno H, Sanz J, Mart\u00ednez de Vega V, Abu-Assi E, I\u00f1iguez A, Fern\u00e1ndez-Ortiz A, Ib\u00e1\u00f1ez B and Fuster V. Triglycerides and Residual Atherosclerotic Risk. J Am Coll Cardiol, 2021; 77: 3031-3041","DOI":"10.1016\/j.jacc.2021.04.059"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ishii M, Seki T, Sakamoto K, Kaikita K, Miyamoto Y, Tsujita K, Masuda I and Kawakami K. Association of short term exposure to Asian dust with increased blood pressure. Sci Rep, 2020; 10: 17630","DOI":"10.1038\/s41598-020-74713-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Fukasawa T, Tanemura N, Kimura S and Urushihara H. Utility of a Specific Health Checkup Database Containing Lifestyle Behaviors and Lifestyle Diseases for Employee Health Insurance in Japan. J Epidemiol, 2020; 30: 57-66","DOI":"10.2188\/jea.JE20180192"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ishii M, Kaikita K, Sakamoto K, Seki T, Kawakami K, Nakai M, Sumita Y, Nishimura K, Miyamoto Y, Noguchi T, Yasuda S, Tsutsui H, Komuro I, Saito Y, Ogawa H and Tsujita K. Characteristics and in-hospital mortality of patients with myocardial infarction in the absence of obstructive coronary artery disease in super-aging society. Int J Cardiol, 2020; 301: 108-113","DOI":"10.1016\/j.ijcard.2019.09.037"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Mansournia MA and Altman DG. Population attributable fraction. BMJ, 2018; 360: k757","DOI":"10.1136\/bmj.k757"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Hanley JA. A heuristic approach to the formulas for population attributable fraction. J Epidemiol Community Health, 2001; 55: 508-514","DOI":"10.1136\/jech.55.7.508"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Satoh H, Nishino T, Tomita K and Tsutsui H. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J, 2006; 70: 227-231","DOI":"10.1253\/circj.70.227"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Iso H, Imano H, Yamagishi K, Ohira T, Cui R, Noda H, Sato S, Kiyama M, Okada T, Hitsumoto S, Tanigawa T and Kitamura A. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis, 2014; 237: 361-368","DOI":"10.1016\/j.atherosclerosis.2014.08.028"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Labreuche J, Touboul PJ and Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis, 2009; 203: 331-345","DOI":"10.1016\/j.atherosclerosis.2008.08.040"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Antonios N, Angiolillo DJ and Silliman S. Hypertriglyceridemia and ischemic stroke. Eur Neurol, 2008; 60: 269-278","DOI":"10.1159\/000157880"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M and Komachi Y. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol, 2001; 153: 490-499","DOI":"10.1093\/aje\/153.5.490"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Imano H, Li J, Tanaka M, Yamagishi K, Muraki I, Umesawa M, Kiyama M, Kitamura A, Sato S and Iso H. Optimal Cut-off Points of Nonfasting and Fasting Triglycerides for Prediction of Ischemic Heart Disease in Japanese General Population: The Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb, 2023; 30: 110-130","DOI":"10.5551\/jat.63358"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Nakano S, Kohsaka S, Chikamori T, Fukushima K, Kobayashi Y, Kozuma K, Manabe S, Matsuo H, Nakamura M, Ohno T, Sawano M, Toda K, Ueda Y, Yokoi H, Gatate Y, Kasai T, Kawase Y, Matsumoto N, Mori H, Nakazato R, Niimi N, Saito Y, Shintani A, Watanabe I, Watanabe Y, Ikari Y, Jinzaki M, Kosuge M, Nakajima K and Kimura T. JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. Circ J, 2022; 86: 882-915","DOI":"10.1253\/circj.CJ-21-1041"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Puri R, Nissen SE, Shao M, Elshazly MB, Kataoka Y, Kapadia SR, Tuzcu EM and Nicholls SJ. Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. Arterioscler Thromb Vasc Biol, 2016; 36: 2220-2228","DOI":"10.1161\/ATVBAHA.116.307601"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Sch\u00f6nbeck U and Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation, 2004; 109: Ii18-26","DOI":"10.1161\/01.CIR.0000129505.34151.23"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol, 2005; 46: 1425-1433","DOI":"10.1016\/j.jacc.2005.05.086"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Liao JK and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol, 2005; 45: 89-118","DOI":"10.1146\/annurev.pharmtox.45.120403.095748"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Drexel H, Tamargo J and Kaski JC. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease? Eur Heart J Cardiovasc Pharmacother, 2023; 9: 570-582","DOI":"10.1093\/ehjcvp\/pvad044"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/7\/32_65334\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:45:49Z","timestamp":1751687149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/7\/32_65334\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65334","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"65334"}}